UiPath | January 12, 2021
The Center for Business Civic Engagement (CBCE) at George Mason University (Mason) declared today the foundation of the Robotic Process Automation (RPA) Initiative in association with driving endeavor RPA programming organization UiPath to decide the effect of RPA on government viability and effectiveness.
The mission of the RPA Initiative is to explore, instruct, and impart how the reception of this arising innovation can improve efficiency, activities, and administration conveyance of public area associations. The RPA Initiative will likewise examine and suggest conceivable administration models and public arrangement activities for RPA sending with regards to the more extensive financial standpoint and the eventual fate of work.
“We are excited to partner with UiPath, a leader and innovator, and look forward to helping determine how RPA usage can improve the working of public sector organizations and succeed in meeting the ever-growing demand for services among stakeholders,” said Dr. David K. Rehr, Director of the Center and a faculty member at the Schar School of Policy and Government at Mason. “The RPA industry has risen to the occasion to help combat the COVID-19 pandemic through civic engagement. This is a critical endeavor and timely moment in our history.”
“Mason has a history of innovation, technology, and studying public policy. We believe the partnership is a great fit and will benefit citizens seeking greater value in public sector programs and initiatives,” said Bobby Patrick, UiPath CMO.
“Our Center at Mason focuses on researching ways to make government more effective and efficient. We have seen recent examples of RPA deployments throughout federal, local, and state governments helping to confront the COVID pandemic while protecting the safety of our citizens,” continued Rehr.
These mission-empowering advancements offer extraordinary assistance in making government programs more effective and delivery government representatives from dull, everyday work, permitting them to be more innovative and inventive in this new typical.
About the Center for Business Civic Engagement at George Mason University (GMU)
The mission of the Center for Business Civic Engagement is to study the impact of the application of business theory and principles to government to determine if government can be both more effective and efficient for its stakeholders.
UiPath has a vision to deliver the Fully Automated Enterprise™, one where companies use automation to unlock their greatest potential. UiPath offers an end-to-end platform for automation, combining the leading Robotic Process Automation (RPA) solution with a full suite of capabilities that enable every organization to rapidly scale digital business operations.
Viasat | October 21, 2021
Viasat Inc., a global communications company, today announced it was awarded a Department of Defense (DoD) contract to provide vulnerability assessment testing and response support under a new pilot program focused on improving the cybersecurity and resilience of DoD weapon systems. Viasat will be the first external cybersecurity team to perform these assessments through the pilot, which aims to drive efficiencies to automate mission and threat-based security assessments at-scale using analytics and a proven methodology for intelligence gathering, threat modeling, vulnerability analysis and exploitation.
As part of the pilot, Viasat will analyze key components within a highly complex, interconnected DoD weapon system architecture that could be vulnerable to an attack. The analysis will also include cyber and software defined radio threat assessments to address networking, Internet of Things and radio frequency interfaces to the weapon system.
"DoD's leadership focus on weapon system cyber resilience is essential. Recent cyberattacks against the U.S. government provide a clear reminder that we must minimize vulnerabilities through active insights and harden core networks. As the battlespace is modernizing quickly, and the use of commercial technologies and systems are being rapidly deployed in DoD's infrastructure, performing robust vulnerability assessment tests is critical to identifying and addressing potential gaps in technology, as well as determining if platforms are potentially vulnerable to attack."
Craig Miller, president, Viasat Government Systems
Miller continued, "Viasat takes a holistic approach to cybersecurity and we're excited to partner with the DoD to provide a comprehensive, scalable vulnerability assessment capability, leveraging the power of analytics-based automation to create efficiencies and enable rapid and continuous evaluations. This will help keep pace with commercial technology development and chart a path to artificial intelligence (AI) and machine learning (ML) driven threat-based cybersecurity assessments."
Viasat was selected based on its extensive experience and award-winning expertise in DoD cybersecurity, as well as its unique view of the threat landscape across global government and commercial services and a customizable approach to information security.
For 35 years, Viasat has been a provider of cybersecurity and information assurance systems to secure U.S. Government, critical infrastructure and commercial networks. As a global satellite internet service provider, Viasat protects its networks and prevents billions of cyberattacks daily. Its history and expertise, paired with expert analysis of data across its network, provides a diverse view of the global cyber threat landscape that allows for the creation and delivery of expert-level security solutions.
Viasat is a global communications company that believes everyone and everything in the world can be connected. For 35 years, Viasat has helped shape how consumers, businesses, governments and militaries around the world communicate. Today, the Company is developing the ultimate global communications network to power high-quality, secure, affordable, fast connections to impact people's lives anywhere they are—on the ground, in the air or at sea. To learn more about Viasat, visit: www.viasat.com, go to Viasat's Corporate Blog, or follow the Company on social media at: Facebook, Instagram, LinkedIn, Twitter or YouTube.
Endo | December 24, 2021
Endo International plc today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Texas.
The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Texas and its subdivisions in exchange for a total payment of $63 million. The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries, and the settlement value should not be extrapolated to any other opioid-related cases or claims.
The Texas settlement resolves, among other things, claims against Endo's subsidiaries in two cases set for trial in Texas state court in 2022: County of Dallas v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77098, and County of Bexar v. Purdue Pharma, L.P., et al., Texas MDL Pretrial Cause No. 2018-77066. The plaintiffs in those cases agreed to sever Endo's subsidiaries from these upcoming trials pending implementation of the settlement.
The Company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. Endo cannot speculate on the likelihood, nature or timing of any outcome.
About Endo International plc
Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.